{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:49:43Z","timestamp":1793155783868,"version":"4.5.0"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Interleukin-17A (IL-17A) inhibitors have revolutionized the treatment of moderate-to-severe plaque psoriasis, but a substantial proportion of patients experience primary non-response during the early treatment phase.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To identify clinical predictors of primary non-response to IL-17A inhibitors and to develop and validate a prediction model for individualized risk assessment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A total of 617 patients initiating IL-17A inhibitors in the Shanghai Psoriasis Effectiveness Evaluation Cohort (SPEECH) were randomly allocated into a training set (\n                      <jats:italic>n<\/jats:italic>\n                      = 370) and an internal validation set (\n                      <jats:italic>n<\/jats:italic>\n                      = 247) in a 6:4 ratio. An external validation cohort included 511 psoriasis patients receiving IL-17A inhibitor across 26 hospitals in China. Primary non-response was defined as failure to achieve \u226575% improvement in the Psoriasis Area and Severity Index (PASI75) at week 12. Logistic regression was used to identify independent predictors, and a multivariable model was developed and validated using receiver operating characteristic (ROC) analysis, calibration curves, and decision curve analysis (DCA).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the training cohort, 23.2% of patients met the definition of primary non-response. Clinical predictors included higher BMI, absence of family history of psoriasis, prior biologic exposure, and higher baseline PASI score. In addition to these clinical factors, failure to achieve PASI40 at week 4 was a strong indicator of subsequent non-response. The final prediction model exhibited strong discrimination (AUC 0.766, 95% CI, 0.690\u20130.842), good calibration between predicted and observed probabilities, and meaningful clinical usefulness as demonstrated by DCA. Performance remained robust in both the internal validation cohort (AUC 0.706) and the external validation cohort (AUC 0.708). An online calculator was developed to facilitate individualized risk estimation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study identified key baseline and early-response predictors of primary non-response to IL-17A inhibitors and established a validated prediction model with clinical utility. The web-based tool may support precision decision-making in psoriasis management by enabling early identification of high-risk patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1725638","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T05:44:17Z","timestamp":1774417457000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Development and validation of a prediction model for primary non-response to IL-17A inhibitors in psoriasis"],"prefix":"10.3389","volume":"13","author":[{"given":"Qian","family":"Yu","sequence":"first","affiliation":[{"name":"Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine","place":["Shanghai, China"]},{"name":"Institute of Psoriasis, Tongji University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxiong","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine","place":["Shanghai, China"]},{"name":"Institute of Psoriasis, Tongji University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine","place":["Shanghai, China"]},{"name":"Institute of Psoriasis, Tongji University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine","place":["Shanghai, China"]},{"name":"Institute of Psoriasis, Tongji University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqi","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine","place":["Shanghai, China"]},{"name":"Institute of Psoriasis, Tongji University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangluyi","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine","place":["Shanghai, China"]},{"name":"Institute of Psoriasis, Tongji University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine","place":["Shanghai, China"]},{"name":"Institute of Psoriasis, Tongji University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanwenke","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine","place":["Shanghai, China"]},{"name":"Institute of Psoriasis, Tongji University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuemeng","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine","place":["Shanghai, China"]},{"name":"Institute of Psoriasis, Tongji University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyuan","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine","place":["Shanghai, China"]},{"name":"Institute of Psoriasis, Tongji University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuling","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine","place":["Shanghai, China"]},{"name":"Institute of Psoriasis, Tongji University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajing","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine","place":["Shanghai, China"]},{"name":"Institute of Psoriasis, Tongji University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis.","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet."},{"key":"B2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40257-015-0162-4","article-title":"Anti-IL-17 medications used in the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review.","volume":"17","author":"Canavan","year":"2016","journal-title":"Am J Clin Dermatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1001\/jamadermatol.2022.2909","article-title":"Drug survival associated with effectiveness and safety of treatment with guselkumab, ixekizumab, Secukinumab, ustekinumab, and adalimumab in patients with psoriasis.","volume":"158","author":"Yiu","year":"2022","journal-title":"JAMA Dermatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1111\/jdv.20739","article-title":"Drug survival of IL-23 and IL-17 inhibitors versus other biologics for psoriasis: a British association of dermatologists biologics and immunomodulators register cohort study.","volume":"39","author":"Motedayen Aval","year":"2025","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1001\/jamadermatol.2025.2714","article-title":"Biopharmaceutical switching in psoriasis treatment: a systematic review and meta-analysis.","volume":"161","author":"Zhang","year":"2025","journal-title":"JAMA Dermatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/bjd.15381","article-title":"Open-label study of etanercept treatment in patients with moderate-to-severe plaque psoriasis who lost a satisfactory response to adalimumab.","volume":"177","author":"Bagel","year":"2017","journal-title":"Br J Dermatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1365-2133.2012.11209.x","article-title":"Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis.","volume":"167","author":"Leman","year":"2012","journal-title":"Br J Dermatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/j.jaad.2025.01.055","article-title":"Early inadequate response to biological agents portends treatment failure at 6 months in patients with psoriasis: a multicenter, prospective cohort study.","volume":"92","author":"Jiang","year":"2025","journal-title":"J Am Acad Dermatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/bjd.16776","article-title":"Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study.","volume":"180","author":"Warren","year":"2019","journal-title":"Br J Dermatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e470","DOI":"10.1111\/jdv.20428","article-title":"Disagreement between physicians\u2019 and patients\u2019 assessment of disease activity in psoriasis: the SPEECH registry study.","volume":"39","author":"Jiang","year":"2025","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s40257-025-00918-y","article-title":"The impact of family history on clinical presentation and biologic treatment response in patients with psoriasis: a multicenter prospective cohort study.","volume":"26","author":"Jiang","year":"2025","journal-title":"Am J Clin Dermatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s13555-024-01134-y","article-title":"Effectiveness of ixekizumab in chinese patients with moderate-severe plaque psoriasis with special area involvement: subanalysis of a prospective, multicenter, observational real-world study.","volume":"14","author":"Li","year":"2024","journal-title":"Dermatol Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1111\/bjd.12610","article-title":"Early clinical response as a predictor of subsequent response to ixekizumab treatment: results from a phase II study of patients with moderate-to-severe plaque psoriasis.","volume":"169","author":"Zhu","year":"2013","journal-title":"Br J Dermatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/09546634.2016.1214671","article-title":"Early clinical response to tofacitinib treatment as a predictor of subsequent efficacy: results from two phase 3 studies of patients with moderate-to-severe plaque psoriasis.","volume":"28","author":"Tan","year":"2017","journal-title":"J Dermatolog Treat."},{"key":"B15","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jaad.2021.06.883","article-title":"Comorbid obesity and history of diabetes are independently associated with poorer treatment response to biologics at 6 months: a prospective analysis in Corrona Psoriasis Registry.","volume":"86","author":"Enos","year":"2022","journal-title":"J Am Acad Dermatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1111\/bjd.20387","article-title":"Association of sex and systemic therapy treatment outcomes in psoriasis: a two-country, multicentre, prospective, noninterventional registry study.","volume":"185","author":"Maul","year":"2021","journal-title":"Br J Dermatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e454","DOI":"10.1111\/jdv.17944","article-title":"Family history of psoriasis: a novel protective factor for therapy switch in patients treated with Secukinumab or Ixekizumab.","volume":"36","author":"Manzo Margiotta","year":"2022","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jaad.2025.02.063","article-title":"Characterization and treatment outcomes of biologic therapy in super-responders and biologic-refractory psoriasis patients: a single-center retrospective study in China.","volume":"93","author":"Liu","year":"2025","journal-title":"J Am Acad Dermatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.jaad.2024.09.060","article-title":"Response to deucravacitinib in psoriasis patients with prior biologic therapy failures: a retrospective study.","volume":"92","author":"Lovell","year":"2025","journal-title":"J Am Acad Dermatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s13555-020-00411-w","article-title":"Brodalumab to the rescue: efficacy and safety of brodalumab in patients with psoriasis and prior exposure or inadequate response to biologics.","volume":"10","author":"Menter","year":"2020","journal-title":"Dermatol Ther."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1725638\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T05:44:18Z","timestamp":1774417458000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1725638\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":20,"alternative-id":["10.3389\/fmed.2026.1725638"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1725638","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"article-number":"1725638"}}